

21st October, 2022

The Dy. General Manager (Listing Dept.) BSE Limited, Corporate Relationship Dept., 1<sup>st</sup> Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 (BSE Scrip Code: 500420) The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

## Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2022

The Presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2022 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

Encl: A/a

\_\_\_\_\_\_



Q2 FY 2022-23

Revenues: Summary



## **Revenue: Summary**

Revenues (Rs cr)	Q2 FY23	Q2 FY22	Gr%
India	1,224	1,087	13%
United States	292	284	3%
Germany	220	251	-12%
Brazil	185	156	19%
Other countries	239	219	10%
Others	131	140	-7%
Total	2,291	2,137	7%

